Skip to content
DataLookout
Menu

SOLUNANCT07598396

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Feb 28, 2028 to Aug 11, 2028
    • Study completion date: Aug 31, 2028 to Aug 11, 2028
    • Site details revised at 1 of 24 sites
  2. Minor Study sites: 22 to 24
  3. Notable Eligibility criteria expanded, about 18 words
    • Study sites: 21 to 22
    • Secondary endpoints: details revised at 4 of 11 entries
    • Publications: details revised at 1 of 1 entry
  4. Minor Trial sites expanded: 17 → 21 locationsv5
  5. Minor Study sites: 15 to 17v4
  6. Minor Start date changed from estimate of May 29, 2026 to May 25, 2026
    • Study sites revised (15)
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants who have achieved remission by Week 76
Timeframe: Up to Week 76

Secondary (11)

Proportion of participants who achieve Definition of Remission in SLE (DORIS) by Week 76
Proportion of participants who achieve Complete Renal Response (CRR) at Weeks 24, 52, 76, and 104
Proportion of participants who achieve Partial Renal Response (PRR) at Weeks 24, 52, 76, and 104
Percentage of participants with adverse events (AEs)
Longitudinal change in titers of anti-double-stranded (ds) DNA
Show 6 moreShow less
Longitudinal changes in complement C3 and C4
Serum concentration of mosunetuzumab
Percentage of participants with anti-drug antibodies (ADAs)
CD19+ absolute counts in blood
Change in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue
Change in Subject's Global Assessment of Disease Activity (SGA)

Arms and interventions

MosunetuzumabExperimental

Participants will receive mosunetuzumab by subcutaneous (SC) injection.

Drugs: Mosunetuzumab

Sites

24 sites in 6 countries

Brazil 7, Mexico 5, Colombia 4, Italy 3, South Africa 3, Argentina 2